

1/10




FIG.1




FIG.2

2/10




FIG. 3A

3/10




FIG.3B

4/10




FIG.3C

5/10




FIG.3D




FIG.3E

7/10




FIG. 3F

8/10

Cryo TEM analysis of Lyophilized VZV




FIG.4A FIG.4B FIG.4C




FIG.5

9/10

Endpoint	Heat-Treated VZV Vaccine (N=65)				Gamma-irradiated VZV Vaccine A (N=63)			
	n	Estimated Response [†]	(95% CI) [†]	p-Value	n	Estimated Response [†]	(95% CI) [†]	p-Value
21-35 Days Post Dose 1								
GMT	62	484.36	(372.10, 630.47)		59	524.74	(410.80, 670.30)	
Geometric Mean Fold Rises from Day 1	62	1.67	(1.38, 2.03)		59	1.72	(1.48, 2.00)	
21-35 Days Post Dose 2								
GMT	62	560.77	(436.73, 720.04)		59	598.98	(474.93, 755.42)	
Geometric Mean Fold Rises from Day 1	62	1.94	(1.61, 2.34)		59	1.96	(1.62, 2.37)	
21-35 Days Post Dose 3								
GMT	62	585.72	(474.47, 723.06)		59	689.98	(543.82, 875.43)	
Geometric Mean Fold Rises from Day 1	62	2.02	(1.68, 2.43)		59	2.26	(1.89, 2.69)	
21-35 Days Post Dose 4								
GMT	62	608.67	(492.50, 752.25)		59	666.27	(532.81, 833.16)	
Geometric Mean Fold Rises from Day 1	62	2.10	(1.78, 2.48)	<0.0001	59	2.18	(1.82, 2.61)	<0.0001
[†] Calculated based on longitudinal regression model (adjusting for pre-vaccination immunogenicity level in the presence of incomplete data), with visit as covariate. The model was fitted in each vaccine group separately. N = Number of subjects vaccinated in each group n = Number of subjects contributing to this immunogenicity analysis (having valid results at baseline and the time points post baseline). gpELISA = Glycoprotein enzyme-linked immunosorbent assay. GMT = Geometric Mean Titer; CI = Confidence interval; VZV = Varicella-zoster virus								

FIG.6

10/10

Endpoint	Gamma-irradiated VZV Vaccine B (N=64)				Gamma-irradiated VZV Vaccine C (N=65)			
	n	Estimated Response [†]	(95% CI) [†]	p-Value	n	Estimated Response [†]	(95% CI) [†]	p-Value
21-35 Days Post Dose 1								
GMT	59	599.04	(465.53, 770.84)		63	646.12	(507.55, 822.52)	
Geometric Mean Fold Rises from Day 1	59	1.91	(1.58, 2.32)		63	1.50	(1.29, 1.75)	
21-35 Days Post Dose 2								
GMT	59	638.49	(505.07, 807.15)		63	712.55	(571.77, 888.00)	
Geometric Mean Fold Rises from Day 1	59	2.04	(1.69, 2.46)		63	1.66	(1.44, 1.92)	
21-35 Days Post Dose 3								
GMT	59	566.13	(454.64, 704.95)		63	601.06	(483.71, 746.88)	
Geometric Mean Fold Rises from Day 1	59	1.81	(1.48, 2.21)		63	1.40	(1.21, 1.62)	
21-35 Days Post Dose 4								
GMT	59	594.03	(479.90, 735.32)		63	676.64	(544.98, 840.10)	
Geometric Mean Fold Rises from Day 1	59	1.90	(1.57, 2.29)	<0.0001	63	1.58	(1.35, 1.84)	<0.0001

[†] Calculated based on longitudinal regression model (adjusting for pre-vaccination immunogenicity level in the presence of incomplete data), with visit as covariate. The model was fitted in each vaccine group separately.
N = Number of subjects vaccinated in each group.
n = Number of subjects contributing to this immunogenicity analysis (having valid results at baseline and the time points post baseline).
gpELISA = Glycoprotein enzyme-linked immunosorbent assay.
GMT = Geometric Mean Titer.
CI = Confidence interval.
VZV = Varicella-zoster virus.

FIG.7